- Home
- DBX vs BLCO Comparison
DBX vs BLCO Comparison
Compare DBX & BLCO Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- DBX
- BLCO
- Stock Information
- Founded
- DBX 2007
- BLCO 1853
- Country
- DBX United States
- BLCO Canada
- Employees
- DBX N/A
- BLCO N/A
- Industry
- DBX Computer Software: Prepackaged Software
- BLCO Ophthalmic Goods
- Sector
- DBX Technology
- BLCO Health Care
- Exchange
- DBX Nasdaq
- BLCO Nasdaq
- Market Cap
- DBX 8.0B
- BLCO 7.0B
- IPO Year
- DBX 2018
- BLCO 2022
- Fundamental
- Price
- DBX $27.06
- BLCO $19.69
- Analyst Decision
- DBX Hold
- BLCO Buy
- Analyst Count
- DBX 7
- BLCO 11
- Target Price
- DBX $28.67
- BLCO $21.30
- AVG Volume (30 Days)
- DBX 3.0M
- BLCO 523.5K
- Earning Date
- DBX 11-07-2024
- BLCO 10-30-2024
- Dividend Yield
- DBX N/A
- BLCO N/A
- EPS Growth
- DBX 9.62
- BLCO N/A
- EPS
- DBX 1.76
- BLCO N/A
- Revenue
- DBX $2,539,600,000.00
- BLCO $4,684,000,000.00
- Revenue This Year
- DBX $2.77
- BLCO $17.44
- Revenue Next Year
- DBX $1.87
- BLCO $6.18
- P/E Ratio
- DBX $15.35
- BLCO N/A
- Revenue Growth
- DBX 3.01
- BLCO 18.01
- 52 Week Low
- DBX $20.68
- BLCO $13.16
- 52 Week High
- DBX $33.43
- BLCO $21.69
- Technical
- Relative Strength Index (RSI)
- DBX 54.36
- BLCO 48.24
- Support Level
- DBX $25.23
- BLCO $19.45
- Resistance Level
- DBX $28.27
- BLCO $20.71
- Average True Range (ATR)
- DBX 0.79
- BLCO 0.55
- MACD
- DBX 0.04
- BLCO -0.15
- Stochastic Oscillator
- DBX 61.95
- BLCO 16.67
About DBX Dropbox Inc.
Dropbox is a leading provider of cloud-storage and content collaboration tools with an emphasis on individuals and SMB. The company was founded in 2007 and was a pioneer in cloud storage and cross-platform file syncing. Utilizing inorganic and organic means, the firm has been working on diversifying its product mix and pivoting away from the cloud-storage space.
About BLCO Bausch + Lomb Corporation
Bausch & Lomb is one of the largest vision care companies in the US. The firm was previously a subsidiary under parent company Bausch Health and it was spun off to become a public company in 2022. It operates in three segments: vision care, surgical, and ophthalmic pharmaceuticals. Vision care is composed of contact lenses, a market that B&L controls 10%, and ocular health products, which includes Biotrue and Lumify. Surgical includes a suite of intraocular lenses, equipment for cataract and vitreoretinal surgeries, as well as surgical instruments. Ophthalmic pharmaceuticals has a diverse lineup of products, including Xipere, Vyzulta, and Lotemax that treat different complications. With over 100 products, B&L has the largest portfolio of eye care prescriptions in the space.